MP68 Inibidores

Os inibidores comuns da MP68 incluem, entre outros, a oligomicina A CAS 579-13-5, a venturicidina A CAS 33538-71-5, o resveratrol CAS 501-36-0, o ácido bongkrekic CAS 11076-19-0 e a rotenona CAS 83-79-4.

MP68 inhibitors act through a variety of mechanisms to prevent the activity of the membrane subunit of ATP synthase. One of these mechanisms is direct inhibition of the F0 subunit, a critical component that facilitates the flow of protons across the mitochondrial membrane, which is essential for ATP synthesis. Some inhibitors achieve this by binding directly to the F0 subunit, effectively blocking proton translocation and thus decreasing ATP synthesis, which is an essential function of MP68. Another inhibitor acts by targeting the F1 subunit, which is responsible for the catalytic conversion of ADP into ATP. By preventing this conversion, the inhibitor indirectly reduces the activity of MP68, since the subunit is unable to perform its function efficiently. In addition, some compounds can inhibit the export of ATP from the mitochondria by targeting the adenine nucleotide translocator, which ultimately leads to a decrease in ATP synthase activity, thus affecting MP68's role in the complex.

Other MP68-inhibiting actions involve disrupting the mitochondrial electron transport chain (ETC), which establishes the proton gradient necessary for ATP synthesis. Inhibitors that target several CTE complexes, such as complexes I, III or IV, lead to a reduction in the proton gradient, subsequently decreasing ATP synthase activity. This indirect inhibition can occur through the binding of these inhibitors to specific CTE complexes, thus preventing the transfer of electrons and the generation of the proton motive force that drives ATP production. The resulting decrease in CTE efficiency has a negative impact on the function of MP68 in the ATP synthase complex, since it depends on the gradient for its activity.